Theratechnologies Inc.
(MENAFN- Baystreet) 10:38 AM EST - Theratechnologies Inc. : Today announced the availability of EGRIFTA WRTM (tesamorelin) for injection for the reduction of excess abdominal fat in adult patients with HIV and lipodystrophy. The announcement follows the approval of EGRIFTA WRTM by the U.S. Food and Drug Administration (FDA) earlier this year. Theratechnologies Inc.
shares T are trading unchanged at $4.50.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Latin America Mobile Payment Market To Hit USD 1,688.0 Billion By 2033
- BTCC Announces Participation In Token2049 Singapore 2025, Showcasing NBA Collaboration With Jaren Jackson Jr.
- PLPC-DBTM: Non-Cellular Oncology Immunotherapy With STIPNAM Traceability, Entering A Global Acquisition Window.
- Bitget Launches PTBUSDT For Futures Trading And Bot Integration
- Ecosync & Carboncore Launch Full Stages Refi Infrastructure Linking Carbon Credits With Web3
- Bitmex And Tradingview Announce Trading Campaign, Offering 100,000 USDT In Rewards And More
More Story
Comments
No comment